Short omalizumab treatment for severe allergic asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether stopping omalizumab for a short time (or using it differently) can be safe for adults with severe allergic asthma who are doing well. It may help some people avoid long-term injections, but only if asthma remains well controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old
- Have been taking omalizumab (OMA) for severe allergic asthma for at least 33 months, prescribed by a lung (pulmonary) specialist
- Your asthma is well controlled: your Asthma Control Test (ACT) score is 18 or higher
- In the past year, you had no more than one asthma flare-up that required steroid tablets or injections (at least 2 days) or doubling steroid doses for at least 2 days
- You must be able and willing to stop omalizumab as the study requires, and you should not be planning pregnancy or switching to another advanced asthma treatment
- You must have health insurance, follow treatments reliably, not be in another research study, and be willing to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called tozorakimab for adults whose asthma is not well controlled despite using their usual inhalers. It aims to see if it can reduce asthma attacks and improve symptoms.
This trial studies whether mepolizumab can reduce ongoing or returning asthma flare-ups in people with severe asthma. If you have severe asthma that still keeps flaring, this may help by targeting a specific inflammation pathway involved in some asthma cases.
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
This trial studies whether starting omalizumab before asthma flare-ups begin can reduce how often children get worsening asthma that needs strong steroid medicine. It is for children with persistent asthma who have signs of allergic/asthma triggers and recent flare-up history.
This study follows patients with severe asthma or chronic hives who are already on omalizumab (Xolair) and are switching to a very similar, lower-cost biosimilar called OMLYCLO. It aims to see if the switch works well in real-world practice.
This study tests if omalizumab, an allergy medicine, can help people with COPD who are allergic to common indoor allergens and have had recent flare-ups. It aims to see if reducing allergic reactions can improve COPD control.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.